Depression of cytochrome P-450 and alterations of protein metabolism in mice treated with the interferon inducer polyriboinosinic acid X polyribocytidylic acid

Interleukin-6 selectively induces drug metabolism to potentiate the genotoxicity of dietary carcinogens in mammary cells

Breast cancer is the most commonly diagnosed malignancy in females, the etiology being multifactorial and includes the role of lifestyle exposure to DNA-damaging chemicals such as dietary carcinogens benzo (a) pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP). Both compounds require cytochrome P450 (CYP)-mediated metabolic activation to DNA-damaging species, and both induce transcriptional responses through the nuclear receptors Aryl hydrocarbon receptor (AhR) and estrogen receptor α (ERα). BaP and PhIP are mammary carcinogens in rodents. Clinically, circulating IL-6 expression is linked with poor prognosis of cancer and 35% of the deaths in breast cancer are linked with inflammation. The objective of this work was to investigate the molecular toxicology and local activation of BaP and PhIP in the presence of IL-6. Our laboratory has previously reported that miR27b can regulate CYP1B1 expression in colorectal cells, here we have investigated if this mechanism is working in mammary cell models, MCF-7 and MDA-MB-231 cells. Treatment (24 h) of cells with BaP (10 nM-10 µM) and PhIP (100 nM-100 µM) significantly induced genetic damage (micronuclei formation) in a dose-dependent manner in both cell lines. This effect was potentiated in the presence of human IL-6 at concentrations reported to be expressed in clinical breast cancer. On its own, IL-6 treatment failed to induce micronuclei frequency above the control levels in these cells. Compared to BaP or PhIP treatment alone, IL-6 plus BaP or PhIP selectively induced CYP1B1 significantly in both cell lines. Additionally, miR27b expression was downregulated by IL-6 treatments and transfection with miR27b inhibitor confirmed that miR27b is a regulator of CYP1B1 in both cell lines. These data show that BaP- and PhIP-induced DNA damage in mammary cells is potentiated by the inflammatory cytokine IL-6 and that inflammation-induced CYP expression, specifically CYP1B1 via miR27b, is responsible for this effect.

Alteration of drug biotransformation and elimination during infection and inflammation

During infection or inflammation, the expression of cytochrome P450 and its dependent biotransformation pathways are modified. This results in a change in the capacity of the liver to handle drugs and in alterations in the production and elimination of endogenous substances throughout the body. The majority of the CYP isoforms are modified at pre-translational steps in protein synthesis, and, in most cases, cytokines are involved as mediators of the response. Recent information suggests that inflammatory responses that are localized to the CNS cause a loss of CYP within the brain. This is accompanied by a parallel down-regulation of CYP in peripheral organs that is mediated by a signaling pathway between the brain and periphery. This review covers the loss that occurs in the major mammalian CYP families in response to infection/inflammation and the mediator pathways that are key to this response.

Regulation of cytochromes P450 during inflammation and infection

Hepatic P450 activities are profoundly affected by various infectious and inflammatory stimuli, and this has clinical and toxicological consequences. Whereas the expression of most P450s in the liver is suppressed, some are induced. Many of the effects observed in vivo can be mimicked by pro-inflammatory cytokines and IFNs, and P450s are differentially regulated by these agents. Therefore, different cytokine profiles and concentrations in the vicinity of the hepatocyte in different models of inflammation may result in qualitatively and quantitatively different effects on populations of P450s. In addition to cytokines, glucocorticoids may have an important role in P450 regulation in stress conditions, including that caused by inflammatory stimuli. Although in many cases the decreases in activity are due primarily to a down-regulation of P450 gene transcription, it is likely that modulation of RNA and protein turnover, as well as enzyme inhibition, contributes to some of the observed effects. The mechanisms whereby these effects are produced may also vary with both the P450 under study and the time course of the effect. The complexity of the P450 response to inflammation and infection means that all of the above factors must be considered when trying to predict the effect of a given infectious or inflammatory condition on the clinical or toxic response of humans or animals to an administered drug or toxin. The question of whether the down-regulation of the hepatic P450 system to inflammation or infection is a homeostatic or pathological response cannot be answered at present. It is difficult to discern the physiological benefit of reducing hepatic P450 activities, unless it is to prevent the generation of reactive oxygen species generated by uncoupled catalytic turnover of the enzymes. On the other hand, as we proposed some years ago [64], the suppression of P450 may be due to the liver's need to utilize its transcriptional machinery and energy for the synthesis of APPs involved in the inflammatory response. In that case, one could ask why the organism has gone to the trouble of employing differential mechanisms for suppression of P450. One answer could be that the response evolved after the divergence of many of the P450 genes, necessitating the evolution of multiple redundant mechanisms for P450 suppression. In contrast to the down-regulation of P450s in the liver, the induction of several forms in this and other tissues suggests a more specific homeostatic role of these effects, e.g., in generation or catabolism of bioactive metabolites.

Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression

1. Cytochrome P4503A (CYP3A) expression was studied in a murine model of infection. Mice were infected with a cystogenic strain of Toxoplasma gondii and microsomes were prepared for liver homogenates and jejunum villus tip enterocytes on day 10 postinfection. Total cytochrome P450 (CYP) and CYP3A were quantitated, and CYP3A activity was determined. 2. In the infected mouse, total CYP and CYP3A contents fell in the liver (-39 and - 49% respectively) and intestine (-43 and - 48 % respectively), as did the rate of metabolism of erythromycin (Ery) and cyclosporine A (CyA), two markers of CYP3A activity (-36 and -26% in the liver, -35 and -58% in the intestine). 3. To determine the mechanism(s) involved in the depression of hepatic CYP3A, infected mice were treated on day 7.5 post-infection with a monoclonal antibody raised against interferon-gamma (anti-IFN-gamma, or from days 7.5 to 10 post-infection with either N(G)-monomethyl-L-arginine (NMMA), an inhibitor of reactive nitrogen intermediates (RNI) production, or N-acetylcysteine (NAC), a reactive oxygen intermediates (ROI) scavenger. 4. Total CYP content was restored in the liver of infected mice treated with anti-IFN-gamma, but with marked interindividual variability. NAC treatment led to a recovery in the liver of total CYP content (+35 %), CYP3A content (total recovery), and the rates of Ery (+59%) and CyA (+87%) metabolism, whereas inconsistent results were obtained with NMMA. These results suggest that NAC, but probably not NMMA, partially protects hepatic CYP3A from Toxoplasma-mediated suppression in mouse.

Short report: interferon-alpha decreases 14C-aminopyrine breath test values in patients with chronic hepatitis C

OBJECTIVE

To investigate the effect of interferon-alpha on cytochrome P-450 dependent microsomal function.

METHODS

The 14C-aminopyrine breath test was performed before, during and after a standard dose of interferon-alpha (3,000,000 units three times per week) was administered for at least six months (nine patients with chronic hepatitis C).

RESULTS

Mean aminopyrine breath test values obtained during therapy were significantly lower than either pre- or post-treatment, the degree of reduction varying widely between individuals. Pre- and post-treatment aminopyrine breath test values did not differ significantly.

CONCLUSION

Interferon therapy is associated with a significant and transient inhibition of cytochrome P-450 activity, which should be taken into account when prescribing concurrent therapy with drugs metabolized by this pathway.

Alpha interferon has no effect on lidocaine metabolism in the rat

Interferons (IFN) inhibit activity of many isoenzymes of the hepatic microsomal cytochrome P-450 system. This inhibition is species specific. Lidocaine is metabolized by cytochrome P-450 III A 4. We investigated in the rat the effect of rat alpha-IFN on lidocaine elimination and on its extraction by the isolated perfused rat liver. To determine elimination, the femoral artery and vein were cannulated. 24 h later, the conscious rat was given lidocaine through the venous catheter and blood was drawn from the arterial catheter for lidocaine determination every 3 min for 20 min. 7 rats were pre-treated with intramuscular rat alpha-IFN 7.5 x 10(5) U, 24 h prior to the experiment and another 4 rats were given saline i.m. The lidocaine elimination rate constant was unchanged, 0.065 min-1 and 0.063 min-1 for the control and IFN groups, respectively. To investigate lidocaine extraction, the isolated perfused rat liver was used. Perfusate samples from the portal and hepatic veins were drawn at 2 min intervals for 20 min, and lidocaine extraction determined. Extraction was determined in two groups of 6 rats each. The first group served as control and these rats were injected with saline only, while in the second group, the rats were pre-treated with rat alpha-IFN 7.5 x 10(5) U. Lidocaine extraction by the isolated perfused rat liver remained unchanged, 97.0 +/- 0.7% and 94.0 +/- 2.4% in the control and IFN treated groups, respectively. It is concluded that the rat alpha-IFN affects neither the elimination nor the extraction of lidocaine.

Effects of interferon, polyriboinosinic acid--polyribocytidilic acid and steroids on the cytochrome P450 system of cultured primary mouse hepatocytes

An earlier study from this laboratory showed that the hepatic murine cytochrome P450 (P450) system was depressed by interferon in vivo but induced in cultured primary hepatocytes. The current investigation attempted to resolve this contradiction. The P450 content of the cells used in the earlier study fell precipitously during the first 24 hr of culture and remained at the same low level throughout another 48 hr of incubation. This failure to maintain the P450 level suggested that the cells may not have been sufficiently viable to support the mechanisms involved in the depressant activity of interferon. Accordingly, a chemically defined medium containing hydrocortisone was devised which supported an acceptable level and function of the P450 system throughout a 72 hr incubation period. Functionality of the P450 system was evaluated by measuring aminopyrine N-demethylase and benzo[a]pyrene hydroxylase activities. When this steroid supplemented medium was used, interferon depressed both activities by about 25%; however, neither activity was affected significantly by poly IC. On the other hand, benzo[a]pyrene hydroxylase activity was depressed by both poly IC and interferon in hepatocytes induced with dexamethasone or with dexamethasone plus 3-methylcholanthrene. These studies emphasize the necessity of maintaining an acceptable level of homeostasis in cultured hepatocytes if one is to derive meaningful interpretations of certain biological events.

The effects of an interferon inducer, polyriboinosinic polyribocytidylic acid on cytochrome P-450 dependent hepatic progesterone metabolism

A time course study on the effects of an interferon inducing agent, polyriboinosinic polyribocytidylic acid (poly rIrC) on the hepatic cytochrome P-450 dependent progesterone metabolism was performed. Administration of a single dose of poly rIrC (10 mg/kg i.p.) to adult male Wistar rats caused a time dependent effect on liver weight, microsomal protein and total cytochrome P-450 levels, as well as the 16 alpha and 6 beta hydroxylation of progesterone. The response was multiphasic, with a maximal depression of both hydroxylase activity 48 hours post-injection, followed by enhanced activity at 72 hours and subsequent return to control activity twenty-four hours later. A second less dramatic rise in the activities followed, bringing the 16 alpha and 6 beta hydroxylase activity to 159% and 141% of their respective control values by 336 hours, at which point of time, the trend appeared to be still on the rise. The enhanced activity at 72 hours was preceded by an increase in serum cortisol and corticosterone levels, the ability of which to enhance the activity of 6 beta hydroxylation of steroids may partly explain the phenomenon.

Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis

We studied the histological and ultrastructural changes in the liver and alterations in the liver test results before, during, and after treatment with human interferon-beta from five patients with hepatitis B e antigen-positive chronic active hepatitis. A daily dose of 3 x 10(6) to 6 x 10(6) units of interferon-beta was given intravenously for four weeks. The total index of periportal and portal inflammation, intralobular degeneration, and focal necrosis before treatment was decreased significantly six months after treatment (P less than 0.05). Ultrastructurally, the structure of endoplasmic reticulum was irregularly shaped or fragmentally decreased during treatment, but these disappeared six or 12 months after treatment. Glycogen particles diminished greatly during treatment. The alanine aminotransferase concentrations in these patients increased during treatment. Serum albumin and cholinesterase levels decreased significantly at the fourth week of treatment (P less than 0.01) and at the third day (P less than 0.01) to the second week (P less than 0.05) of treatment, respectively. These results suggest that interferon-beta injures endoplasmic reticulum and glycogen areas and damages the cholinesterase activity in the early stage of treatment and protein synthesis in patients with hepatitis B e antigen-positive chronic active hepatitis.

Suppression of P450IIC12 gene expression and elevation of actin messenger ribonucleic acid levels in the livers of female rats after injection of the interferon inducer poly rI.poly rC

Interferons and interferon inducers cause a reduction in hepatic microsomal cytochrome P450 [AH, reduced-flavoprotein: oxygen oxidoreductase (RH hydroxylating), EC 1.14.14.1] content and drug-metabolizing activities in experimental animals. In the present study, the acute effects of administration of the interferon inducer polyriboinosinic acid.polyribocytidylic acid (poly rI.poly rC) to female rats on expression of the microsomal apoprotein and hepatic mRNA for P450IIC12, a constitutive enzyme comprising a significant fraction of the total P450 in untreated female rats, were examined. Poly rI.poly rC treatment (10 mg/kg, i.p.) caused a suppression of P450IIC12 apoprotein that was of greatest magnitude (47% of control levels) 24 hr after injection. P450IIC12 was still suppressed significantly (P less than 0.05) 48 hr after treatment. The time courses of suppression and recovery of P450IIC12 protein, as well as the magnitude of the effect, were similar to those of total microsomal P450 measured spectrophotometrically. P450IIC12 mRNA levels were also suppressed by the poly rI.poly rC treatment, reaching 29% of control values within 24 hr. Comparison of the kinetics of suppression of the P450IIC12 mRNA and apoprotein indicated that at least part of the suppression of the protein is mediated pretranslationally. However, the existence of a posttranslational component could not be excluded. Concomitant with the suppression of P450IIC12, actin mRNA content was found to be elevated by at least 3.6-fold in the livers of poly rI.poly rC-treated female rats, with the maximum effect occurring 12 hr after injection of the drug. This effect of poly rI.poly rC on expression of actin mRNA appeared to be at least partially sex-specific, since in a previous study [Morgan ET and Norman CA, Drug Metab Dispos 18: 649-653, 1990] a significant effect of the interferon inducer on actin expression was not observed in livers of male rats.

Perturbation of metabolism and disposition of cyclophosphamide by interferon and poly I:C, an interferon inducer, in mice

The effects of interferon and poly I:C on the metabolism and disposition of cyclophosphamide were investigated in mice. Elimination of cyclophosphamide from the blood was decreased in mice treated 24 hr previously with interferon (2.5 x 10(6) U/kg, intraperitoneally) or poly I:C (10 mg/kg, intraperitoneally). The blood half-life of cyclophosphamide in interferon or poly I:C-pretreated mice was prolonged to a first order of disappearance of 29.3 and 41.6 min., respectively, compared to 19.0 min. in control mice. Also, the rate of formation of activated cyclophosphamide was delayed and the peak blood level of activated cyclophosphamide was not as high in poly I:C-pretreated and interferon-pretreated mice as in control mice. The decreased elimination and elevated blood levels of activated cyclophosphamide were reflected by changes in its antitumour activity and toxicity in the mice. In 9,000 x g supernatants prepared from the liver homogenate of mice treated with interferon or poly I:C, the oxidation of cyclophosphamide in vitro has decreased by 29 and 37%, respectively. However, the addition of these agents to normal 9,000 x g supernatant suspensions had no effect on cyclophosphamide oxidation. Modulation of the metabolism and disposition resulted from depressed levels of cytochrome P-450 in the hepatic microsomes of the mice administered interferon or poly I:C.

The effect of IFN-alpha-Con1 on hepatic cytochrome P-450 and protein synthesis and degradation in hepatic microsomes

Interferon and its inducers are well known to depress drug biotransformation in the liver by decreasing the levels of cytochrome P-450 in that organ. We now report that IFN-alpha-Con1, which was constructed from the most frequently observed amino acid sequences in human alpha-interferon subtypes, causes a loss in cytochrome P-450 which could be prevented by pretreating animals with either puromycin or actinomycin D. This suggests that the loss in drug biotransformation is mediated via the production of an intermediate protein. When the turnover of microsomal protein was examined this interferon appeared to depress the synthesis of proteins with molecular weights 46-60 kd and had little effect on the synthesis of other proteins. The in vitro translation of proteins of molecular weights 45-60 kd was also depressed in an in vitro translation system using mRNA isolated from the livers of interferon treated hamsters. Interferon had no effect on the degradation of microsomal proteins of all molecular weights. It is concluded that interferon probably depresses the levels of cytochrome P-450 in the liver by decreasing the synthesis of the apoprotein and that interferon has little effect on the degradation of the hemoprotein.

Depression of drug metabolizing activity in the human liver by interferon-alpha

The depressant effect of interferon-alpha on drug metabolizing activity in the liver has been investigated in 12 patients with chronic active hepatitis B. 7-methoxy-coumarin (7-MC) O-demethylase and 7-ethoxycoumarin (7-EC) O-deethylase, in specimens obtained by liver biopsy, were measured before and after interferon treatment. 7-MC and 7-EC O-dealkylase activity were significantly reduced after interferon treatment, from 13.4 to 9.24 nmol.g-1 liver.min-1, and from 3.22 to 2.16 nmol.g-1 liver.min-1, respectively. The magnitude of the fall varied widely between individual patients. The study provides the first direct evidence that interferon-alpha can impair the activity of drug metabolizing enzymes in the human liver.

Inhibition of carcinogenesis by minor anutrient constituents of the diet

A continuing study of chemopreventive agents has focused on several categories of naturally occurring compounds that inhibit carcinogen activation and are effective in preventing carcinogen-induced neoplasia when administered at short time-intervals before carcinogen challenge. The inhibitory compounds are: aromatic isothiocyanates found in cruciferous vegetables, monoterpenes present in citrus fruits and caraway-seed oil, and organosulphur compounds occurring in Allium species. Preliminary work indicates that glucobrassicin and indoles existing in cruciferous vegetables also have these attributes. Almost all carcinogens that are consumed in food require metabolic activation. Thus, inhibition of carcinogen activation reactions could be effective against this type of exposure. In addition, three naturally occurring compounds, i.e. phenethyl isothiocyanate, D-limonene and dipropyl sulphide inhibit activation of the tobacco-specific carcinogen NNK, and accordingly may have the capacity to diminish carcinogenic response to exposures to tobacco. The property of cruciferous vegetables, orange oil, benzyl isothiocyanate, and D-limonene, to act as both blocking and suppressing agents has been discussed. Two possible mechanisms for this multi-phase activity were presented. The first is that these inhibitory substances activate a complex integrated defence mechanism against toxic compounds which entails both blocking and suppressing components. The blocking component is the initial line of defence, and the suppressing component constitutes a 'fail-safe' backup to assure that if any of the toxic material attacks cellular constituents, its effects will be nullified. The second possible mechanism considered is that the inhibitors, because of high reactivity, have multiple biological effects that are separate and not part of a single, coordinated response. Inhibitors that have both blocking and suppressing effects could be particularly useful as chemopreventive agents. A simple interim classification of foods in terms of their potential impact on the occurrences of cancer has been proposed.

In vitro translational activity of messenger-RNA isolated from mice treated with the interferon inducer, polyriboinosinic acid.polyribocytidylic acid

Treatment of mice with interferon and interferon inducers causes down regulation of a number of hepatic proteins. In a previous publication it was demonstrated that these treatments depress hepatic protein synthesis and increase protein degradation, particularly of the endoplasmic reticulum Gooderham NJ and Mannering GJ, Arch Biochem Biophys 250: 418-425, 1986. In the present study the effects of polyriboinosinic acid.polyribocytidylic acid (poly IC) treatment on mouse hepatic RNA levels and the translation of this RNA in a cell-free system were examined. Poly IC treatment of mice increased hepatic poly (A+) RNA levels. The translation of isolated poly(A+)RNA was evaluated at various intervals after the administration of poly IC. Translation was marginally increased at 3-6 hr after treatment and depressed after 12-18 hr. Antibodies were employed to examine the effects of poly IC treatment on specific polypeptides in order to evaluate the in vitro translation of mRNAs for tyrosine aminotransferase and albumin; translation of these proteins was biphasic with pronounced depression. These studies indicate that in vivo interferon may regulate gene expression by altering levels of hepatic proteins via increased transcription and decreased translation.

Inhibition of carcinogenesis by naturally-occurring and synthetic compounds

A continuing study of chemopreventive agents has focused on three categories of naturally-occurring compounds that inhibit carcinogen activation and are effective in preventing carcinogen-induced neoplasia when administered at short time intervals prior to carcinogen challenge. The three are: aromatic isothiocyanates found in cruciferous vegetables, monoterpenes from citrus fruits and caraway seed oils, and organosulfur compounds occurring in Allium species. The short time-interval effects could be significant in terms of their impact on responses of humans to carcinogen exposures. The capacity of sodium cyanate, cruciferous vegetables, orange oil, benzyl isothiocyanate, and D-limonene to act as both blocking and suppressing agents has been discussed. Two possible mechanisms for this multiphase activity were presented. The first is that these inhibitory substances activate a complex integrated defense mechanism against toxic compounds which entails both blocking and suppressing components. The blocking component is the initial line of defense, and the suppressing component constitutes a "fail-safe" backup to assure that if any of the toxic material attacks cellular constituents, its effects will be nullified. The second possible mechanism considered is that the inhibitors, because of high reactivity, have multiple biological effects that are separate and not part of a single, coordinated response. Inhibitors that have both blocking and suppressing effects could be particularly useful as chemopreventive agents.

Rat but not human interferons suppress hepatic oxidative drug metabolism in rats

An animal model suitable for in vivo studies of interferon-mediated suppression of hepatic oxidative drug metabolism has been developed. Rats were injected with either recombinant human interferon alpha A, recombinant human interferon gamma, recombinant rat interferon gamma, or vehicle and experiments were performed 24 h later. In some animals theophylline elimination was determined twice (10 days apart), once after interferon and once after vehicle. Theophylline clearance was also determined in the isolated perfused rat liver after pretreatment of animals with interferon or vehicle. Pretreatment of animals with rat interferon gamma significantly reduced theophylline clearance in the intact rat but neither human interferon alpha A nor human interferon gamma altered theophylline elimination in vivo. Similar results were observed in the isolated perfused rat liver. We then examined whether the effects of interferon on hepatic drug metabolism were generalized or confined to individual cytochrome P450 isozymes; androstenedione hydroxylation pathways were used as catalytic probes for individual cytochrome P450 isozymes. Rat interferon gamma (but not human interferon alpha A) decreased levels of total hepatic microsomal P450 and reduced androstenedione 16 beta-hydroxylation. The formation of three other hydroxylated androstenedione metabolites appeared reduced to a similar extent, although these changes were not significant. It is concluded that autologous but not heterologous interferons impair oxidative drug metabolism in the rat. The reduction of hepatic P450 produced by interferon may result from the suppression of multiple isozymes.

Modulation of benzene toxicity by polyinosinic-polycytidilic acid, an interferon inducer

Repeated intraperitoneal administration of benzene (1.0 ml/kg body wt.) for 3 days produced leucopenia, lymphocytopenia and significantly decreased body wt. (P less than 0.001) and organ weights of thymus (P less than 0.001) and spleen (P less than 0.001) in female albino rats. Total iron content, lipid peroxidation and superoxide dismutase activity of the liver and bone marrow were significantly increased as a result of benzene exposure. Low molecular weight (LMW) bleomycin detectable iron content was accumulated in bone marrow, whereas hepatic LMW iron was not detectable after benzene intoxication to rats. Prior administration of single dose (250 micrograms/100 g body wt.) of Poly IC, an interferon inducer with immunomodulating potential was found to be ameliorate some of the adverse effects of benzene as well as restoration of hepatic architecture histologically. Superoxide dismutase activity, lipid peroxidation, total iron content and LMW iron content (bone marrow) were normalised. Pretreatment of animals with Poly IC was able to enhance the SRBC antibody titre in benzene-treated animals. This study suggests that the beneficial effects of Poly IC in the amelioration of the acute toxicity of benzene has clinical significance.

Effects of poly I: poly C on rat pulmonary and hepatic cytochromes P-450 and b5

Interferon inducing agents such as poly I:poly C have been shown to reduce the hepatic hemoproteins cytochromes P-450 and b5 along with the associated monooxygenase activities [el Azhary and Mannering, Molec. Pharmac. 15, 698 (1979)]. In a previous study [Kikkawa et al., Lab. Invest. 50, 62 (1984)], we demonstrated that the interferon inducing agent poly I:poly C reduces pulmonary microsomal hemoprotein by 50% when administered to rats. The current investigation was conducted to characterize these changes in more detail and compare them to analogous changes in the liver. Compared to controls, cytochrome P-450 in both the lungs and livers of poly I:poly C treated rats declined by 40% at 24 hr and 55% at 48 hr (P less than 0.01). By 72 hr the decline was only 25%. In contrast, cytochrome b5 levels declined by less than 30% of control values during the first 48 hr following poly I:poly C injection (P less than 0.01) and returned to control levels by 72 hr. These changes in both cytochrome P-450 and b5 were reflected in decreases in pulmonary microsomal hemoprotein. Benzphetamine-N-demethylase activity declined by 45% in lung microsomes at 48 hr (P less than 0.01) after injection of poly I:poly C, while 7-ethoxycoumarin-O-deethylase (P less than 0.05) and 7-ethoxyresorufin-O-deethylase activities declined by approximately 41%. In the liver from these same poly I:poly C treated groups, benzphetamine-N-demethylase declined by 66% (P less than 0.05), while 7-ethoxycoumarin-O-deethylase and 7-ethoxyresorufin-O-deethylase activities declined by 60% (P less than 0.02 and P less than 0.05 respectively).